

John K Hsiao

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8842817/john-k-hsiao-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58
papers

12,152
citations

37
h-index

59
g-index

59
ext. papers

13,349
ext. citations

8
avg, IF

5.13
L-index

#	Paper	IF	Citations
58	A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensemble and on multivariate algorithms, to characterize late onset Alzheimer's disease. <i>Scientific Reports</i> , 2020 , 10, 12063	4.9	5
57	Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 797-808	5.2	5
56	Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. <i>Schizophrenia Bulletin</i> , 2015 , 41, 449-59	1.3	52
55	Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. <i>American Journal of Psychiatry</i> , 2011 , 168, 831-9	11.9	180
54	Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. <i>American Journal of Psychiatry</i> , 2009 , 166, 583-90	11.9	65
53	Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Biological Psychiatry</i> , 2009 , 66, 1013-22	7.9	81
52	Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009 , 107, 1-12	3.6	106
51	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. <i>Schizophrenia Research</i> , 2008 , 100, 39-52	3.6	45
50	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. <i>Schizophrenia Research</i> , 2008 , 101, 273-86	3.6	222
49	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008 , 103, 104-9	3.6	59
48	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008 , 105, 175-87	3.6	179
47	Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. <i>American Journal of Psychiatry</i> , 2008 , 165, 844-54	11.9	230
46	What CATIE found: results from the schizophrenia trial. <i>Psychiatric Services</i> , 2008 , 59, 500-6	3.3	89
45	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007 , 7, 103-11	2.2	20
44	Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. <i>Archives of General Psychiatry</i> , 2007 , 64, 1259-68		45
43	Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007 , 64, 633-47		781
42	Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. <i>American Journal of Psychiatry</i> , 2007 , 164, 428-36	11.9	212

41	Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. <i>American Journal of Psychiatry</i> , 2007 , 164, 415-27	11.9	117
40	Cost-effectiveness of schizophrenia pharmacotherapy. <i>American Journal of Psychiatry</i> , 2007 , 164, 678; author reply 678-9	11.9	6
39	Interpreting the results of the CATIE study. <i>Psychiatric Services</i> , 2006 , 57, 139	3.3	15
38	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Psychiatric Publishing)</i> , 2006 , 4, 539-552	1.1	
37	Barriers to employment for people with schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 411-7	11.9	327
36	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006 , 163, 600-610	11.9	682
35	Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>New England Journal of Medicine</i> , 2006 , 355, 1525-38	59.2	875
34	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006 , 163, 611-622	11.9	283
33	Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 2080-9	11.9	218
32	Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. <i>American Journal of Psychiatry</i> , 2006 , 163, 600-10	11.9	359
31	Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. <i>American Journal of Psychiatry</i> , 2006 , 163, 611-22	11.9	153
30	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. <i>New England Journal of Medicine</i> , 2005 , 353, 1209-23	59.2	4423
29	Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. <i>Schizophrenia Research</i> , 2005 , 80, 19-32	3.6	885
28	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005 , 187, 529-36	5.4	68
27	National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. <i>American Journal of Geriatric Psychiatry</i> , 2001 , 9, 346-360	6.5	103
26	Medication-free Intervals and Schizophrenia Research Editors' Introduction. <i>Schizophrenia Bulletin</i> , 1997 , 23, 1-1	1.3	3
25	The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. <i>Neuropsychopharmacology</i> , 1993 , 9, 277-91	8.7	151
24	Dose-dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans. <i>Psychopharmacology</i> , 1993 , 111, 295-300	4.7	9

23	Clinical investigation of monoamine neurotransmitter interactions. <i>Psychopharmacology</i> , 1993 , 112, S76-84	4.4	19
22	ECT treatment does not enhance neuroendocrine responses to serotonergic challenge. <i>Journal of Psychopharmacology</i> , 1992 , 6, 501-8	4.6	2
21	Regional brain metabolism as predictors of clozapine response. <i>Clinical Neuropharmacology</i> , 1992 , 15 Suppl 1 Pt A, 399A-400A	1.4	1
20	Lithium administration modulates platelet Gi in humans. <i>Life Sciences</i> , 1992 , 50, 227-33	6.8	25
19	In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. <i>Journal of Neurochemistry</i> , 1992 , 59, 200-5	6	67
18	Quantitative examination of tissue concentration profiles associated with microdialysis. <i>Journal of Neurochemistry</i> , 1992 , 58, 931-40	6	134
17	Quantitative microdialysis: analysis of transients and application to pharmacokinetics in brain. <i>Journal of Neurochemistry</i> , 1991 , 57, 103-19	6	129
16	Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. <i>Brain Research</i> , 1991 , 538, 333-6	3.7	37
15	Quantitative microdialysis. <i>Handbook of Behavioral Neuroscience</i> , 1991 , 7, 47-80		30
14	Effects of different semipermeable membranes on in vitro and in vivo performance of microdialysis probes. <i>Journal of Neurochemistry</i> , 1990 , 54, 1449-52	6	121
13	Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients. <i>Psychiatry Research</i> , 1990 , 31, 39-47	9.9	41
12	Methodology of microdialysis of neostriatum in hemiparkinsonian nonhuman primates. <i>Experimental Neurology</i> , 1990 , 110, 181-6	5.7	20
11	In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. <i>Experimental Neurology</i> , 1990 , 110, 187-93	5.7	26
10	Diagnosing diagnoses. Receiver operating characteristic methods and psychiatry. <i>Archives of General Psychiatry</i> , 1989 , 46, 664-7		219
9	The effects of intravenous clomipramine on neurohormones in normal subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989 , 68, 632-7	5.6	55
8	Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects. <i>Psychopharmacology</i> , 1989 , 99, 508-14	4.7	31
7	Activation in young rats induced by LY134046, an inhibitor of phenylethanolamine N-methyltransferase. <i>Psychopharmacology</i> , 1989 , 98, 240-4	4.7	1
6	Monoamine neurotransmitter interactions and the prediction of antidepressant response. <i>Archives of General Psychiatry</i> , 1987 , 44, 1078-83		52

5	Cardiovascular response to speaking in schizophrenics. <i>Psychiatry Research</i> , 1987 , 22, 69-79	9.9	2
4	The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 42, 547-54	6.1	37
3	ECT and Neurological Disorders. <i>Convulsive Therapy</i> , 1987 , 3, 121-136		13
2	Is there paradoxical growth hormone response to thyrotropin-releasing hormone in depression?. <i>Biological Psychiatry</i> , 1986 , 21, 595-600	7.9	15
1	A study of the TRH test in a family with psychiatric illness: a reflection on the TRH test as a state-trait marker. <i>Biological Psychiatry</i> , 1985 , 20, 570-2	7.9	22